Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%

Reuters

2025/08/28

Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%

Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562276055"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562276055\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562276055?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-28 22:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562276055","market":"nz","top_or_hot":-1,"title":"Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCharmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-28 22:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02289","symbol_name":"创美药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250828:nNDL7vmltC:1","article_id":"2562276055","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562276055","pubTimestamp":1756390892,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"02289":"创美药业"},"translate_title":"Charmacy Pharmaceutical报告2025年上半年营业收入下降8.18%，净利润下降18.72%；每股收益下降18.73%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02289":0.9},"content_text":"Charmacy Pharmaceutical Reports 8.18% Drop in Operating Revenue and 18.72% Decline in Net Profit for H1 2025; EPS Falls by 18.73%\n    \n\n        Charmacy Pharmaceutical Co. Ltd. has announced its unaudited consolidated interim results for the six months ended 30 June 2025. The company reported a decrease in operating revenue, with figures amounting to RMB 2.155 billion, down 8.18% from RMB 2.347 billion in the same period of 2024. Total profit also saw a decline, registering at RMB 32.629 million, a 16.18% decrease compared to RMB 38.928 million in the previous year. Net profit attributable to shareholders of the parent company decreased by 18.72% to RMB 21.739 million from RMB 26.747 million in 2024. Basic and diluted earnings per share were reported at RMB 0.2013, marking an 18.73% decline from RMB 0.2477 in the previous year. The company's core operations remain focused on pharmaceutical distribution and related services, with all operations and revenue generated within the People's Republic of China. No changes in significant accounting policies or estimates were reported for the period.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charmacy Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,event,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}